These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 2253197)

  • 41. Phase I and pharmacokinetic study of 502U83 (an arylmethylaminopropanediol) in cancer patients.
    Lam KS; Alberts DS; Peng YM; Brodar F; Matias B; Modiano M; Tuttle R; Sol Lucas V; Wargin W
    Anticancer Drugs; 1992 Jun; 3(3):219-24. PubMed ID: 1525401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics of pyrazoloacridine in the rhesus monkey.
    Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
    Cancer Res; 1991 Oct; 51(20):5467-70. PubMed ID: 1913666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I clinical investigation of amonafide.
    Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
    J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I trial and clinical pharmacology of elsamitrucin.
    Raber MN; Newman RA; Newman BM; Gaver RC; Schacter LP
    Cancer Res; 1992 Mar; 52(6):1406-10. PubMed ID: 1540949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole).
    Ames MM; Loprinzi CL; Collins JM; van Haelst-Pisani C; Richardson RL; Rubin J; Moertel CG
    Cancer Res; 1990 Jul; 50(13):3905-9. PubMed ID: 2191768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.
    O'Dwyer PJ; Laub PB; DeMaria D; Qian M; Reilly D; Giantonio B; Johnston AL; Wu EY; Bauman L; Clendeninn NJ; Gallo JM
    Clin Cancer Res; 1996 Oct; 2(10):1685-92. PubMed ID: 9816117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 1 trial and assay of rubidazone (NSC 164011) in patients with advanced solid tumors.
    Kovach JS; Ames MM; Sternad ML; O'Connell MJ
    Cancer Res; 1979 Mar; 39(3):823-8. PubMed ID: 427770
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I clinical and pharmacological study of chloroquinoxaline sulfonamide.
    Rigas JR; Tong WP; Kris MG; Orazem JP; Young CW; Warrell RP
    Cancer Res; 1992 Dec; 52(23):6619-23. PubMed ID: 1423306
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule.
    Cobb PW; Havlin KA; Kuhn JG; Craig JB; Harman GS; Luther JS; Turner JN; Weiss GR; Tweedy DA; Koeller J
    Sel Cancer Ther; 1991; 7(2):85-91. PubMed ID: 1754731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors.
    Vogel CL; Gorowski E; Davila E; Eisenberger M; Kosinski J; Agarwal RP; Savaraj N
    Invest New Drugs; 1987; 5(2):187-98. PubMed ID: 3115912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetic study of rhizoxin.
    Bissett D; Graham MA; Setanoians A; Chadwick GA; Wilson P; Koier I; Henrar R; Schwartsmann G; Cassidy J; Kaye SB
    Cancer Res; 1992 May; 52(10):2894-8. PubMed ID: 1581905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design.
    Gadgeel SM; Boinpally RR; Heilbrun LK; Wozniak A; Jain V; Redman B; Zalupski M; Wiegand R; Parchment R; LoRusso PM
    Invest New Drugs; 2003 Feb; 21(1):63-74. PubMed ID: 12795531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule.
    Rigas JR; Francis PA; Miller VA; Tong WP; Roistacher N; Kris MG; Orazem JP; Young CW; Warrell RP
    Cancer Chemother Pharmacol; 1995; 35(6):483-8. PubMed ID: 7882456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deoxyspergualin: phase I clinical, immunologic and pharmacokinetic study.
    Havlin KA; Kuhn JG; Koeller J; Boldt DH; Craig JB; Brown TD; Weiss GR; Cagnola J; Phillips J; Harman G
    Anticancer Drugs; 1995 Apr; 6(2):229-36. PubMed ID: 7795272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I study of retelliptine dihydrochloride (SR 95325 B) using a single two-hour intravenous infusion schedule.
    Kattan J; Durand M; Droz JP; Mahjoubi M; Marino JP; Azab M
    Am J Clin Oncol; 1994 Jun; 17(3):242-5. PubMed ID: 8192111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalators.
    Havlin KA; Kuhn JG; Craig JB; Weiss GR; Koeller J; Turner JN; Luther JS; Clark G; Bair KW; Wargin W
    Anticancer Drugs; 1991 Aug; 2(4):357-63. PubMed ID: 1797191
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical pharmacology of deoxyspergualin in patients with advanced cancer.
    Muindi JF; Lee SJ; Baltzer L; Jakubowski A; Scher HI; Sprancmanis LA; Riley CM; Vander Velde D; Young CW
    Cancer Res; 1991 Jun; 51(12):3096-101. PubMed ID: 2039989
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.
    Raghavan D; Bishop J; Sampson D; Grygiel J; Woods R; Coates A; Fox R
    Cancer Chemother Pharmacol; 1986; 16(2):160-4. PubMed ID: 3948303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacokinetics of 3-deazaguanine.
    Pendyala L; Creaven PJ; Whitfield LR
    Cancer Chemother Pharmacol; 1991; 29(1):33-6. PubMed ID: 1742847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG).
    Erdélyi-Tóth V; Kerpel-Fronius S; Kanyár B; Eckhardt S
    Cancer Chemother Pharmacol; 1986; 16(3):257-63. PubMed ID: 3698167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.